odprn logo ODPRN

Drug Policy and Evaluation

The ODPRN has conducted multiple studies evaluating drug policy and effectiveness which have impacted societal outcomes and improved healthcare system efficiency. This research includes a wide breadth of work ranging from large drug class reviews to specific rapid responses resulting from decision makers’ pressing initiatives.


Recent Research

Self-monitoring of blood glucose: Impact of quantity limits in public drug formularies on provincial costs across Canada

For most patients with diabetes, routine use of blood glucose test strips (BGTS) has not been shown to be beneficial, yet the economic implications of broad publicly funded reimbursement for BGTS are substantial. We assessed the potential impact of BGTS quantity limits on utilization and costs for 6 publicly funded drug plans across Canada.

Association of a blood glucose test strip quantity-limit policy with patient outcomes

In 2013, Ontario was one of the first payers to introduce a policy limiting reimbursements for BGTS aligned with recommendations from the Canadian Diabetes Association. This study investigates the impact of this policy on patient outcomes among adults with diabetes in Ontario.

High strength opioid formulations in Ontario: By the numbers

This rapid analysis reports the utilization of high strength formulations of long-acting hydromorphone, morphine and fentanyl and their usage among palliative care patients to inform discussions on reimbursement changes within the Ontario Drug Benefit (ODB) program.


All Research on Drug Policy and Evaluation



Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.